MARKET

BBOT

BBOT

BridgeBio Oncology Therapeutics, Inc
NASDAQ
10.66
-0.59
-5.24%
Closed 19:23 02/17 EST
OPEN
11.25
PREV CLOSE
11.25
HIGH
11.45
LOW
10.54
VOLUME
218.73K
TURNOVER
0
52 WEEK HIGH
14.87
52 WEEK LOW
8.50
MARKET CAP
852.68M
P/E (TTM)
53.38
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BBOT last week (0209-0213)?
Weekly Report · 1d ago
BridgeBio Oncology Therapeutics to Present at Major Healthcare Investor Conferences
Reuters · 5d ago
BBOT to Participate in Upcoming Investor Healthcare Conferences
Barchart · 5d ago
BridgeBio Oncology Therapeutics Grants Stock Options Under 2025 Inducement Plan
Reuters · 6d ago
This Olema Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday
Benzinga · 6d ago
BridgeBio Oncology Initiated at Buy by Stifel
Dow Jones · 6d ago
BridgeBio Oncology Price Target Announced at $23.00/Share by Stifel
Dow Jones · 6d ago
Stifel Initiates Coverage On BridgeBio Oncology with Buy Rating, Announces Price Target of $23
Benzinga · 6d ago
More
About BBOT
Bridgebio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing the pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. Its pipeline of RAS-targeted oncology drug candidates includes BBO-8520, BBO-10203, and BBO-11818. BBO-8520 (NCT06343402) is a direct inhibitor of KRASG12C in both the ON and OFF states that is being evaluated both as monotherapy and in combination with pembrolizumab in the Phase 1 ONKORAS-101 trial for patients with KRASG12C mutant non-small cell lung cancer. BBO-10203 (NCT06625775) is an orally bioavailable small molecule that selectively and specifically blocks the physical interaction between RAS and PI3Ka, resulting in the inhibition of RAS-driven PI3Ka-AKT signaling in tumors without the risk of hyperglycemia. BBO-11818 (NCT06917079) is a panKRAS inhibitor targeting mutant KRAS in both the ON and OFF states with strong potency against KRASG12D and KRASG12V mutants.

Webull offers BridgeBio Oncology Therapeutics Inc stock information, including NASDAQ: BBOT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BBOT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BBOT stock methods without spending real money on the virtual paper trading platform.